Kanjinti

Patients w/ metastatic breast cancer (MBC) who have tumors that overexpress HER2 as monotherapy for those who have received ≥1 chemotherapy regimen for their metastatic disease; in combination w/ paclitaxel in those who have not received chemotherapy for their metastatic disease; in combination w/ aromatase inhibitor for postmenopausal patients w/ hormone-receptor +ve MBC. Patients w/ HER2 +ve early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) & RT if applicable; in combination w/ paclitaxel or docetaxel following adjuvant chemotherapy w/ doxorubicin & cyclophosphamide; in combination w/ adjuvant chemotherapy consisting of docetaxel & carboplatin; in combination w/ neoadjuvant chemotherapy followed by adjuvant Kanjinti therapy for locally advanced (including inflammatory) disease or tumours >2 cm in diameter. Patients whose tumours have either HER2 overexpression or gene amplification. In combination w/ capecitabine or 5-fluorouracil & cisplatin for patients w/ HER2 +ve metastatic adenocarcinoma of stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for metastatic disease. Patients w/ metastatic gastric cancer (MGC) whose tumours have HER2 overexpression.

IV MBC Treatment duration: Until disease progression or unmanageable toxicity. Wkly schedule: Loading dose: 4 mg/kg as a 90-min infusion. Subsequent doses: 2 mg/kg wkly. Can be administered as a 30-min infusion if prior dose was well-tolerated. 3-wkly schedule: Loading dose: 8 mg/kg followed by 6 mg/kg 3 wk later & then 6 mg/kg repeated at 3-wkly intervals over approx 90 min infusion. Subsequent doses: Can be administered as 30-min infusion if the initial loading dose was well tolerated. EBC Treatment duration: 1 yr or until disease recurrence or unmanageable toxicity, whichever occurs 1st. 3-wkly schedule: Loading dose: 8 mg/kg. Maintenance dose: 6 mg/kg at 3-wkly intervals, beginning 3 wk after loading dose. Alternative wkly schedule (wkly regimen concomitantly w/ paclitaxel following chemotherapy w/ doxorubicin & cyclophosphamide): Loading dose: 4 mg/kg, followed by 2 mg/kg every wk. MGC Treatment duration: Until disease progression or unmanageable toxicity. 3-wkly schedule: Loading dose: 8 mg/kg followed by 6 mg/kg 3 wk later & then 6 mg/kg repeated at 3-wkly interval over approx 90 min infusion. Subsequent doses: Can be administered as 30-min infusion if initial loading dose was well tolerated.

Hypersensitivity to trastuzumab, murine proteins or hyaluronidase. Severe dyspnoea at rest due to complications of advanced malignancy or requiring supplementary O₂ therapy.

Targeted Cancer Therapy

L01FD01 - trastuzumab ; Belongs to the class of HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors. Used in the treatment of cancer.

POM